Tempus AI (NASDAQ:TEM) Stock Price Down 4.3% – Here’s Why

Tempus AI, Inc. (NASDAQ:TEM)’s share price traded down 4.3% on Tuesday . The stock traded as low as $48.87 and last traded at $49.62. 3,190,208 shares changed hands during mid-day trading, a decline of 65% from the average session volume of 9,131,566 shares. The stock had previously closed at $51.86.

Analyst Ratings Changes

Several research analysts recently issued reports on TEM shares. Piper Sandler reaffirmed a “neutral” rating and set a $70.00 target price (up from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Wolfe Research began coverage on shares of Tempus AI in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target for the company. Stifel Nicolaus cut shares of Tempus AI from a “buy” rating to a “hold” rating and increased their price objective for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Bank of America boosted their target price on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a report on Friday, December 13th. Finally, Loop Capital decreased their target price on Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research note on Tuesday, January 14th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $56.36.

Tempus AI Stock Down 1.6 %

The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The company has a fifty day moving average price of $44.32 and a 200 day moving average price of $47.87.

Insider Buying and Selling at Tempus AI

In related news, CEO Eric P. Lefkofsky sold 85,788 shares of the company’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $53.39, for a total transaction of $4,580,221.32. Following the completion of the sale, the chief executive officer now owns 5,771,787 shares in the company, valued at approximately $308,155,707.93. This represents a 1.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Andrew Polovin sold 51,504 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $42.39, for a total transaction of $2,183,254.56. Following the transaction, the executive vice president now directly owns 246,085 shares in the company, valued at $10,431,543.15. The trade was a 17.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,862,758 shares of company stock worth $79,585,675.

Institutional Investors Weigh In On Tempus AI

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. First Horizon Advisors Inc. purchased a new position in shares of Tempus AI in the 3rd quarter worth about $30,000. FNY Investment Advisers LLC bought a new position in shares of Tempus AI during the 4th quarter worth $67,000. Vestor Capital LLC purchased a new stake in Tempus AI in the 3rd quarter worth about $153,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Tempus AI in the fourth quarter valued at approximately $178,000. Finally, Stifel Financial Corp bought a new position in Tempus AI in the 3rd quarter worth approximately $218,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.